Clinical Trial Details
| Trial ID: | L2132 |
| Source ID: | NCT00659282 |
| Associated Drug: | Biphasic Insulin Aspart |
| Title: | Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes |
| Acronym: | IMPROVE™ |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: biphasic insulin aspart |
| Outcome Measures: | Primary: Incidence of major hypoglycaemic events reported as serious adverse drug reactions, during treatment | |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | CHILD, ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 57610 |
| Study Type: | OBSERVATIONAL |
| Study Designs: | Observational Model: |Time Perspective: p |
| Start Date: | 2006-09-11 |
| Completion Date: | 2008-11-15 |
| Results First Posted: | |
| Last Update Posted: | 2018-01-12 |
| Locations: | Novo Nordisk Investigational Site, Mississauga, L4W 4XI, Canada|Novo Nordisk Investigational Site, Beijing, Beijing, 100004, China|Novo Nordisk Investigational Site, Vouliagment, 16671, Greece|Novo Nordisk Investigational Site, Bangalore, 560001, India|Novo Nordisk Investigational Site, Teheran, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Rome, 00144, Italy|Novo Nordisk Investigational Site, Tokyo, 1000005, Japan|Novo Nordisk Investigational Site, Seoul, 137-920, Korea, Republic of|Novo Nordisk Investigational Site, Warszawa, PL-02-274, Poland|Novo Nordisk Investigational Site, Moscow, 119330, Russian Federation|Novo Nordisk Investigational Site, Riyadh, 3542, Saudi Arabia |
| URL: | https://clinicaltrials.gov/show/NCT00659282 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|